➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Medtronic
Moodys
Colorcon
McKesson

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CESAMET

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Cesamet

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00272207 ↗ A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia Completed Valeant Canada Limited Phase 2 2006-04-01 The purpose of the study is to determine whether or not the drug Nabilone significantly reduces pain and improves quality of life in patients with fibromyalgia.
NCT00272207 ↗ A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia Completed Winnipeg Regional Health Authority Phase 2 2006-04-01 The purpose of the study is to determine whether or not the drug Nabilone significantly reduces pain and improves quality of life in patients with fibromyalgia.
NCT00380913 ↗ Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NEMA Research, Inc. Phase 4 2006-09-01 This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to diabetic peripheral neuropathy.
NCT00380965 ↗ Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy Completed NEMA Research, Inc. Phase 4 2006-10-01 This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to chemotherapy-induced neuropathic pain in patients with cancer.
NCT00381264 ↗ Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis Completed NEMA Research, Inc. Phase 4 2006-09-01 This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to Multiple Sclerosis.
NCT00384410 ↗ Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients Unknown status Valeant Pharmaceuticals International, Inc. Phase 2 2005-12-01 Sleep disturbance is perhaps one of the most prevalent complaints of patients with long-standing painful conditions. Nabilone is a medication that is approved by Health Canada as an anti-emetic (prevent vomiting) for patients undergoing chemotherapy. Nabilone, due to its sleep promoting properties, is sometimes prescribed by physicians to pain patients to help improve their sleep. However, there is no direct research evidence to either support or refute this practice. This study will investigate if nabilone is effective in improving sleep in insomnia and pain patients.
NCT00384410 ↗ Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients Unknown status University Health Network, Toronto Phase 2 2005-12-01 Sleep disturbance is perhaps one of the most prevalent complaints of patients with long-standing painful conditions. Nabilone is a medication that is approved by Health Canada as an anti-emetic (prevent vomiting) for patients undergoing chemotherapy. Nabilone, due to its sleep promoting properties, is sometimes prescribed by physicians to pain patients to help improve their sleep. However, there is no direct research evidence to either support or refute this practice. This study will investigate if nabilone is effective in improving sleep in insomnia and pain patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cesamet

Condition Name

Condition Name for Cesamet
Intervention Trials
Multiple Sclerosis 2
Obsessive-Compulsive Disorder 2
Diabetic Neuropathies 2
Nausea and Vomiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cesamet
Intervention Trials
Neuralgia 3
Multiple Sclerosis 2
Peripheral Nervous System Diseases 2
Diabetic Neuropathies 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cesamet

Trials by Country

Trials by Country for Cesamet
Location Trials
United States 7
Canada 7
Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cesamet
Location Trials
Florida 3
New York 2
Texas 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cesamet

Clinical Trial Phase

Clinical Trial Phase for Cesamet
Clinical Trial Phase Trials
Phase 4 5
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cesamet
Clinical Trial Phase Trials
Completed 7
Not yet recruiting 4
Unknown status 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cesamet

Sponsor Name

Sponsor Name for Cesamet
Sponsor Trials
Valeant Pharmaceuticals International, Inc. 3
NEMA Research, Inc. 3
New York State Psychiatric Institute 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cesamet
Sponsor Trials
Other 17
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Johnson and Johnson
Medtronic
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.